ResearcherShihezi UniversityActive in the last 2 years

Ketao Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5220-7239; OpenAlex author ID A5006470519. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2024: 2 papers

Papers 2

Transcriptomics and molecular docking reveal the potential mechanism of lycorine against pancreatic cancer. Last author DOI 10.1016/j.phymed.2023.155128 ↗
Bufadienolides from Chansu Injection Synergistically Enhances the Antitumor Effect of Erlotinib by Inhibiting the KRAS Pathway in Pancreatic Cancer. Last author DOI 10.3390/ph17121696 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xin Zhou · 1 shared paper, 2024 · strength 0.23
- Paper Transcriptomics and molecular docking reveal the potential mechanism of lycorine against pancreatic cancer. DOI 10.1016/j.phymed.2023.155128 ↗
Zhenli Guo · 1 shared paper, 2024 · strength 0.23
- Paper Transcriptomics and molecular docking reveal the potential mechanism of lycorine against pancreatic cancer. DOI 10.1016/j.phymed.2023.155128 ↗
Yanli Guo · 1 shared paper, 2024 · strength 0.22
- Paper Bufadienolides from Chansu Injection Synergistically Enhances the Antitumor Effect of Erlotinib by Inhibiting the KRAS … DOI 10.3390/ph17121696 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.